141 related articles for article (PubMed ID: 22204610)
1. Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era.
Karam I; Nichol A; Woods R; Tyldesley S
Radiat Oncol; 2011 Dec; 6():181. PubMed ID: 22204610
[TBL] [Abstract][Full Text] [Related]
2. Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras.
Karam I; Hamilton S; Nichol A; Woods R; Speers C; Kennecke H; Tyldesley S
Radiat Oncol; 2013 Jan; 8():12. PubMed ID: 23302543
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review.
Dawood S; Gonzalez-Angulo AM; Albarracin C; Yu TK; Hortobagyi GN; Buchholz TA; Woodward WA
Cancer; 2010 Jul; 116(13):3084-92. PubMed ID: 20564633
[TBL] [Abstract][Full Text] [Related]
4. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
6. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer.
Ono M; Ando M; Yunokawa M; Nakano E; Yonemori K; Matsumoto K; Kouno T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
Int J Clin Oncol; 2009 Feb; 14(1):48-52. PubMed ID: 19225924
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
[TBL] [Abstract][Full Text] [Related]
8. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
10. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
11. Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients.
Fokas E; Henzel M; Hamm K; Grund S; Engenhart-Cabillic R
Tumori; 2012 Nov; 98(6):768-74. PubMed ID: 23389365
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
Olson EM; Najita JS; Sohl J; Arnaout A; Burstein HJ; Winer EP; Lin NU
Breast; 2013 Aug; 22(4):525-31. PubMed ID: 23352568
[TBL] [Abstract][Full Text] [Related]
13. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Gori S; Montemurro F; Spazzapan S; Metro G; Foglietta J; Bisagni G; Ferzi A; Silva RR; Gamucci T; Clavarezza M; Stocchi L; Fabi A; Cognetti F; Torrisi E; Crivellari D
Ann Oncol; 2012 Jun; 23(6):1436-41. PubMed ID: 22039084
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
15. Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment.
Le Scodan R; Massard C; Jouanneau L; Coussy F; Gutierrez M; Kirova Y; Lerebours F; Labib A; Mouret-Fourme E
J Neurooncol; 2012 Jan; 106(1):169-76. PubMed ID: 21735114
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
18. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
20. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems.
Viani GA; Castilho MS; Salvajoli JV; Pellizzon AC; Novaes PE; Guimarães FS; Conte MA; Fogaroli RC
BMC Cancer; 2007 Mar; 7():53. PubMed ID: 17386108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
